Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17

In addition to reporting, in accompanying papers, their individual analyses of mapping the neurofibromatosis type 1 (NF1) gene on chromosome 17, members of the International Consortium for NF1 Linkage contributed their data for our joint analysis to determine the exact sequence of flanking markers and to obtain precise estimates and confidence limits of the recombination fractions for the closest markers, in anticipation of clinical use. With specimens from 142 families and more than 700 affected persons, eight teams used 31 markers in the pericentric region of chromosome 17 to perform 13,838 genotypings. With the combined data, we used the computer program CRI-MAP to build the most likely sequence of loci by sequentially adding single loci to a fixed pair of loci and separately calculating the likelihood of all permutations of four consecutive loci. The best order is pter-pA10-41-EW301-centromere (p17H8)-pHHH202-NF1-EW206-EW207-EW203++ +-CRI-L581-CRI-L946-HOX2-NGFR-qter. The total genetic distance from pA10-41 to NGFR is 26 cM in males and 56 cM in females, and the overall difference in sex-specific maps is statistically significant (P = .006). The upper 99% confidence limits of the recombination fraction of the closest proximal marker, pHHH202, is 4%, and that for the closest distal marker, EW206, is 9%. These limits should decrease with the use of additional probes and the further evaluation of DNA from the six persons showing multiple recombinations within short genetic distances. Clinical application is technically feasible with currently available markers, although its appropriate use for prenatal and presymptomatic diagnosis requires further discussion and evaluation.

Multipoint linkage analysis in neurofibromatosis type I: an international collaboration.

Familial cancer syndromes reflect an inherited predisposition to develop benign and malignant tumors. Clinically, the cancers occur at an earlier age and involve multiple foci of tumor formation at multiple sites. In the past 10 years, the molecular basis of many of these cancer syndromes have been unraveled with the advent of powerful genetic technologies. Entities which were hypothesized to be related on the basis of clinical features have now been shown to be linked or disparate through genetic analysis. This article reviews some of the recent advances in the clinical and molecular aspects of familial cancer syndromes that involve the skin. (J Am Acad Dermatol 2000;42:939–69.) Learning Objective: After completing this article, the reader should become (1) fluent with some basic genetic principles underlying the mechanisms of cancer predisposition and positional cloning and (2) aware of the recent breakthroughs in the identification of familial cancer syndrome disease genes.

https://www.jaad.org/article/S0190-9622(00)90285-8/pdf

Update on familial cancer syndromes and the skin

Methods of classical segregation analysis were applied to a sample of 129 sibships with one or more individuals affected by neurofibromatosis-1 (NF-1). The sample consists only of subjects with NF-1; all the probands had been referred for genetic counselling because of cafe-au-lait spots, and a diagnostic protocol was invariably applied. No deviation from the segregation ratio expected for a fully penetrant Mendelian dominant gene was observed. A maximum likelihood estimate of the proportion of sporadic cases was obtained, and the mutation rate was estimated to be 6.5 x 10(-5) gametes per generation (95% CI 5.0-8.1).

Neurofibromatosis-1: a maximum likelihood estimation of mutation rate

von Recklinghausen neurofibromatosis (NF1) is the most common hereditary syndrome predisposing to neoplasia. NF1 is an autosomal dominant disease caused by a single gene which maps to chromosome 17q11.2. The most common symptomatic manifestation of NF1 is the benign neurofibroma. Our previous studies of tumors in NF1, studies which detected a loss of heterozygosity for DNA markers from the NF1 region of chromosome 17 in malignant tumors, did not detect a loss in neurofibromas. We report here that a more extensive study, including the analysis of neurofibromas from 19 unrelated NF1 patients by using seven probes, failed to detect a single instance of loss of heterozygosity. This finding suggests that neurofibromas are either polyclonal or monoclonal in origin but arise by a mechanism different from that of NF1 malignancies. In order to investigate the first possibility, we analyzed neurofibromas from female NF1 patients by using an X chromosome-specific probe, from the phosphoglycerokinase (PGK) gene, which detects an RFLP. The detected alleles carry additional recognition sites for the methylation-sensitive enzyme HpaII, so that the allele derived from the active X chromosome is digested by HpaII while the one from the hypermethylated, inactive X chromosome is not. We analyzed neurofibromas from 30 unrelated females with NF1. Eight patients were heterozygous for the PGK RFLP. By this assay, neurofibromas from all eight appeared monoclonal in origin. These results suggest that benign neurofibromas in NF1 arise by a mechanism that is different from that of malignant tumors.(ABSTRACT TRUNCATED AT 250 WORDS)

The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin.

The von Recklinghausen neurofibromatosis (NF1) gene has been mapped to the pericentromeric region of chromosome 17. We conducted linkage analyses of NF1 by using 10 polymorphic DNA markers from this chromosomal region. We ascertained 20 American Caucasian NF1 families (163 individuals, 98 NF1 affected) in Michigan and Ohio and also studied a large family ascertained primarily in North Carolina. The following markers were used in this study: HHH202, TH17.19, D17Z1, ERBA1, EW203, EW206, EW207, EW301, CRI-L581, and CRI-L946. NF1 did not recombine with either TH17.19 or HHH202 in any of the informative meioses surveyed (maximum lod scores of 17.04 and 7.21, respectively, at a recombination fraction of .00), indicating that these markers map very close to the NF1 gene. We also report evidence of three instances of recombination between NF1 and the centromeric marker D17Z1 (maximum lod score of 13.43 at a recombination fraction of .04), as well as two crossovers between pairs of marker loci. We find no evidence of locus heterogeneity, and our results support the localization of the NF1 gene to proximal chromosome 17q.

J. L. Lieberman

Papers

A refined genetic map of the region of chromosome 17 surrounding the von Recklinghausen neurofibromatosis (NF1) gene.

Linkage analysis of von Recklinghausen neurofibromatosis to DNA markers on chromosome 17